Bcl-2 anticorps (Internal Region)
-
- Antigène Voir toutes Bcl-2 (BCL2) Anticorps
- Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))
-
Épitope
- Internal Region
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp Bcl-2 est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)
- Specificité
- Bcl-2 Antibody detects endogenous levels of total Bcl-2.
- Purification
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
- Immunogène
- A synthesized peptide derived from human Bcl-2, corresponding to a region within the internal amino acids.
- Isotype
- IgG
- Top Product
- Discover our top product BCL2 Anticorps primaire
-
-
- Indications d'application
- WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20 °C. Stable for 12 months from date of receipt.
- Date de péremption
- 12 months
-
-
Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro." dans: Molecular medicine reports, Vol. 16, Issue 1, pp. 208-214, (2018) (PubMed).
: "
-
Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro." dans: Molecular medicine reports, Vol. 16, Issue 1, pp. 208-214, (2018) (PubMed).
-
- Antigène
- Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))
- Autre désignation
- BCL2 (BCL2 Produits)
- Synonymes
- anticorps Bcl-2, anticorps PPP1R50, anticorps bcl-2, anticorps AW986256, anticorps C430015F12Rik, anticorps D630044D05Rik, anticorps D830018M01Rik, anticorps BCL-2, anticorps Bcl2, anticorps BCL2, apoptosis regulator, anticorps B cell leukemia/lymphoma 2, anticorps B-cell CLL/lymphoma 2a, anticorps B-cell CLL/lymphoma 2 protein, anticorps BCL2, anticorps Bcl2, anticorps bcl2a, anticorps BCL-2
- Sujet
-
Description: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
Gene: BCL2
- Poids moléculaire
- 28kDa
- ID gène
- 596
- UniProt
- P10415
- Pathways
- Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling
-